These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 32621970)

  • 1. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease.
    Petta S; Sebastiani G; Viganò M; Ampuero J; Wai-Sun Wong V; Boursier J; Berzigotti A; Bugianesi E; Fracanzani AL; Cammà C; Enea M; Grottes MD; Di Marco V; Younes R; Keyrouz A; Mazzola S; Mendoza Y; Pennisi G; Romero-Gomez M; Craxì A; de Ledinghen V
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):806-815.e5. PubMed ID: 32621970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
    Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
    Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B.
    Chon YE; Jung ES; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Jung KS; Kim SU
    J Clin Gastroenterol; 2012 Jul; 46(6):518-25. PubMed ID: 22688146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.
    Semmler G; Yang Z; Fritz L; Köck F; Hofer BS; Balcar L; Hartl L; Jachs M; Stopfer K; Schedlbauer A; Neumayer D; Maurer J; Müllner-Bucsics T; Simbrunner B; Scheiner B; Trauner M; Mandorfer M; Reiberger T; Bauer DJM
    Gastroenterology; 2023 Oct; 165(4):1041-1052. PubMed ID: 37442301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.
    Gawrieh S; Vilar-Gomez E; Wilson LA; Pike F; Kleiner DE; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Kowdley KV; Hameed B; Tonascia J; Loomba R; Sanyal AJ; Chalasani N;
    J Hepatol; 2024 Oct; 81(4):600-608. PubMed ID: 38762169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease.
    Braude M; Roberts S; Majeed A; Lubel J; Prompen J; Dev A; Sievert W; Bloom S; Gow P; Kemp W
    Liver Int; 2023 Jan; 43(1):90-99. PubMed ID: 36050821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease.
    Thorhauge KH; Semmler G; Johansen S; Lindvig KP; Kjærgaard M; Hansen JK; Torp N; Hansen CD; Andersen P; Hofer BS; Gu W; Israelsen M; Mandorfer M; Reiberger T; Trebicka J; Thiele M; Krag A;
    J Hepatol; 2024 Jul; 81(1):23-32. PubMed ID: 38428644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease.
    Mendoza Y; Cocciolillo S; Murgia G; Chen T; Margini C; Sebastiani G; Berzigotti A
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):3017-3025.e6. PubMed ID: 32289534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Liver Stiffness, Measured by Magnetic Resonance Elastography, Associated With Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis.
    Eaton JE; Sen A; Hoodeshenas S; Schleck CD; Harmsen WS; Gores GJ; LaRusso NF; Gossard AA; Lazaridis KN; Venkatesh SK
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1576-1583.e1. PubMed ID: 31683058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease.
    Grimaudo S; Pipitone RM; Pennisi G; Celsa C; Cammà C; Di Marco V; Barcellona MR; Boemi R; Enea M; Giannetti A; Spatola F; Marchesini G; Craxì A; Petta S
    Clin Gastroenterol Hepatol; 2020 Apr; 18(4):935-944.e3. PubMed ID: 31419571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.
    Ajmera V; Kim BK; Yang K; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Idilman R; Gumussoy M; Oz DK; Erden A; Quach NE; Tu X; Zhang X; Noureddin M; Allen AM; Loomba R
    Gastroenterology; 2022 Oct; 163(4):1079-1089.e5. PubMed ID: 35788349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis.
    Kim SU; Lee JH; Kim DY; Ahn SH; Jung KS; Choi EH; Park YN; Han KH; Chon CY; Park JY
    PLoS One; 2012; 7(5):e36676. PubMed ID: 22574212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease.
    Yu H; Huang Y; Li M; Jiang H; Yang B; Xi X; Smayi A; Wu B; Yang Y
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2169-2181. PubMed ID: 38946401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease.
    Scheiner B; Steininger L; Semmler G; Unger LW; Schwabl P; Bucsics T; Paternostro R; Ferlitsch A; Trauner M; Reiberger T; Mandorfer M
    Liver Int; 2019 Jan; 39(1):127-135. PubMed ID: 30107095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria.
    Elhence A; Anand A; Biswas S; Vaishnav M; Yadav R; Das P; Panwar R; Agarwal S; Gamanagatti S; Kumar R; Shalimar
    Dig Dis Sci; 2023 Mar; 68(3):1016-1025. PubMed ID: 35670897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.
    Lee SW; Huang DQ; Bettencourt R; Ajmera V; Tincopa M; Noureddin N; Amangurbanova M; Siddiqi H; Madamba E; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Yoneda M; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
    Aliment Pharmacol Ther; 2024 Jan; 59(1):80-88. PubMed ID: 37968251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.